Status:
COMPLETED
Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Conditions:
Malaria
Eligibility:
All Genders
3-59 years
Phase:
PHASE3
Brief Summary
Malaria in African countries remains an important cause of mortality and morbidity among young children. The global malaria control strategies include prompt treatment with an effective antimalarial d...
Detailed Description
Goals and Objectives 1. The goal of this project was to determine the degree to which morbidity from malaria can be prevented in children who receive intermittent preventive treatment(IPTc) with SP p...
Eligibility Criteria
Inclusion
- Age between 3 months and 59 months at enrolment.
- Informed consent obtained from parents or legal guardians.
- No current participation in another malaria intervention trial
- Permanent residence in the study area with no intention of leaving during the surveillance period.
Exclusion
- Previous adverse reaction to treatment with SP, amodiaquine or Coartem. If this is unknown, then a history of allergic reaction to any drug.
- Temporary residence in the study area
- Lack of informed consent
- Presence of a severe, chronic illness such as severe malnutrition or AIDS, likely to interfere with evaluation of the trial results.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
1312 Patients enrolled
Trial Details
Trial ID
NCT00944840
Start Date
September 1 2008
End Date
August 1 2009
Last Update
January 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Farafenni Field Station, MRC Laboratories
Farafenni, North Bank Division, The Gambia